Academic Journal
Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma
| العنوان: | Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma |
|---|---|
| المؤلفون: | Susan Y. Wu, MD, Penny Q. Fang, MD, MBA, Ethan B. Wang, BA, Sairah Ahmed, MD, Madeleine Duvic, MD, Preetesh Jain, MD, Luis E. Malpica Castillo, MD, Ranjit Nair, MD, Raphael E. Steiner, MD, Paolo Strati, MD, Auris O. Huen, MD, PharmD, Swaminathan P. Iyer, MD, Chelsea C. Pinnix, MD, PhD, Bouthaina S. Dabaja, MD, Jillian R. Gunther, MD, PhD |
| المصدر: | Advances in Radiation Oncology, Vol 8, Iss 6, Pp 101279- (2023) |
| بيانات النشر: | Elsevier |
| سنة النشر: | 2023 |
| المجموعة: | Directory of Open Access Journals: DOAJ Articles |
| مصطلحات موضوعية: | Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Purpose: Purpose: Radiation therapy (RT) and the antibody-drug conjugate brentuximab vedotin (BV) are standard-of-care treatment options for patients with certain B and T-cell lymphomas; however, there are limited data exploring the safety of concurrent BV and RT (BVRT). Methods and Materials: We performed a single institutional retrospective review of 44 patients who received BVRT. Results: Twenty percent of patients (9/44) developed new grade 2 or higher (G2+) hematologic toxicity (HT) after BVRT, which was associated with radiation dose (median dose of 35 Gy in those with new G2+ HT compared with 15 Gy in those without; P < .001). Acute G2+ elevation in aspartate transaminase or alanine transaminase level was associated with administration of concurrent chemotherapy with BVRT (57% vs 21%; P = .047) but was not associated with any RT factors. Local control (LC) was achieved in 24 of 42 patients (57%) with available follow-up. Ten patients (23%) proceeded to stem cell transplant or cellular therapy after BVRT at a median of 48 days (interquartile range, 27-188 days). At last follow-up, 10 patients (23%) remained without evidence of disease. Conclusions: Our analysis demonstrates that the combination of BV and RT is well tolerated, though care should be taken during RT planning to reduce the risk of HT. This combination can be considered for patients in need of both local and systemic disease control. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 2452-1094 |
| Relation: | http://www.sciencedirect.com/science/article/pii/S2452109423001082; https://doaj.org/toc/2452-1094; https://doaj.org/article/d902d9f49c7047199b12871407803f0e |
| DOI: | 10.1016/j.adro.2023.101279 |
| الاتاحة: | https://doi.org/10.1016/j.adro.2023.101279 https://doaj.org/article/d902d9f49c7047199b12871407803f0e |
| رقم الانضمام: | edsbas.EB8644FB |
| قاعدة البيانات: | BASE |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
edsbas BASE edsbas.EB8644FB 961 3 Academic Journal academicJournal 960.976379394531 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.EB8644FB&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doi.org/10.1016/j.adro.2023.101279# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) [1] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edsbas&genre=article&issn=24521094&ISBN=&volume=&issue=&date=20230101&spage=&pages=&title=Advances in Radiation Oncology, Vol 8, Iss 6, Pp 101279- (2023&atitle=Safety%20of%20Concurrent%20Radiation%20Therapy%20With%20Brentuximab%20Vedotin%20in%20the%20Treatment%20of%20Lymphoma&id=DOI:10.1016/j.adro.2023.101279 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Susan+Y%2E+Wu%2C+MD%22">Susan Y. Wu, MD</searchLink><br /><searchLink fieldCode="AR" term="%22Penny+Q%2E+Fang%2C+MD%2C+MBA%22">Penny Q. Fang, MD, MBA</searchLink><br /><searchLink fieldCode="AR" term="%22Ethan+B%2E+Wang%2C+BA%22">Ethan B. Wang, BA</searchLink><br /><searchLink fieldCode="AR" term="%22Sairah+Ahmed%2C+MD%22">Sairah Ahmed, MD</searchLink><br /><searchLink fieldCode="AR" term="%22Madeleine+Duvic%2C+MD%22">Madeleine Duvic, MD</searchLink><br /><searchLink fieldCode="AR" term="%22Preetesh+Jain%2C+MD%22">Preetesh Jain, MD</searchLink><br /><searchLink fieldCode="AR" term="%22Luis+E%2E+Malpica+Castillo%2C+MD%22">Luis E. Malpica Castillo, MD</searchLink><br /><searchLink fieldCode="AR" term="%22Ranjit+Nair%2C+MD%22">Ranjit Nair, MD</searchLink><br /><searchLink fieldCode="AR" term="%22Raphael+E%2E+Steiner%2C+MD%22">Raphael E. Steiner, MD</searchLink><br /><searchLink fieldCode="AR" term="%22Paolo+Strati%2C+MD%22">Paolo Strati, MD</searchLink><br /><searchLink fieldCode="AR" term="%22Auris+O%2E+Huen%2C+MD%2C+PharmD%22">Auris O. Huen, MD, PharmD</searchLink><br /><searchLink fieldCode="AR" term="%22Swaminathan+P%2E+Iyer%2C+MD%22">Swaminathan P. Iyer, MD</searchLink><br /><searchLink fieldCode="AR" term="%22Chelsea+C%2E+Pinnix%2C+MD%2C+PhD%22">Chelsea C. Pinnix, MD, PhD</searchLink><br /><searchLink fieldCode="AR" term="%22Bouthaina+S%2E+Dabaja%2C+MD%22">Bouthaina S. Dabaja, MD</searchLink><br /><searchLink fieldCode="AR" term="%22Jillian+R%2E+Gunther%2C+MD%2C+PhD%22">Jillian R. Gunther, MD, PhD</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Advances in Radiation Oncology, Vol 8, Iss 6, Pp 101279- (2023) ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Elsevier ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2023 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => Directory of Open Access Journals: DOAJ Articles ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Medical+physics%2E+Medical+radiology%2E+Nuclear+medicine%22">Medical physics. Medical radiology. Nuclear medicine</searchLink><br /><searchLink fieldCode="DE" term="%22R895-920%22">R895-920</searchLink><br /><searchLink fieldCode="DE" term="%22Neoplasms%2E+Tumors%2E+Oncology%2E+Including+cancer+and+carcinogens%22">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</searchLink><br /><searchLink fieldCode="DE" term="%22RC254-282%22">RC254-282</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Purpose: Purpose: Radiation therapy (RT) and the antibody-drug conjugate brentuximab vedotin (BV) are standard-of-care treatment options for patients with certain B and T-cell lymphomas; however, there are limited data exploring the safety of concurrent BV and RT (BVRT). Methods and Materials: We performed a single institutional retrospective review of 44 patients who received BVRT. Results: Twenty percent of patients (9/44) developed new grade 2 or higher (G2+) hematologic toxicity (HT) after BVRT, which was associated with radiation dose (median dose of 35 Gy in those with new G2+ HT compared with 15 Gy in those without; P < .001). Acute G2+ elevation in aspartate transaminase or alanine transaminase level was associated with administration of concurrent chemotherapy with BVRT (57% vs 21%; P = .047) but was not associated with any RT factors. Local control (LC) was achieved in 24 of 42 patients (57%) with available follow-up. Ten patients (23%) proceeded to stem cell transplant or cellular therapy after BVRT at a median of 48 days (interquartile range, 27-188 days). At last follow-up, 10 patients (23%) remained without evidence of disease. Conclusions: Our analysis demonstrates that the combination of BV and RT is well tolerated, though care should be taken during RT planning to reduce the risk of HT. This combination can be considered for patients in need of both local and systemic disease control. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 2452-1094 ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => http://www.sciencedirect.com/science/article/pii/S2452109423001082; https://doaj.org/toc/2452-1094; https://doaj.org/article/d902d9f49c7047199b12871407803f0e ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1016/j.adro.2023.101279 ) Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://doi.org/10.1016/j.adro.2023.101279<br />https://doaj.org/article/d902d9f49c7047199b12871407803f0e ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.EB8644FB ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1016/j.adro.2023.101279
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Medical physics. Medical radiology. Nuclear medicine
[Type] => general
)
[1] => Array
(
[SubjectFull] => R895-920
[Type] => general
)
[2] => Array
(
[SubjectFull] => Neoplasms. Tumors. Oncology. Including cancer and carcinogens
[Type] => general
)
[3] => Array
(
[SubjectFull] => RC254-282
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Susan Y. Wu, MD
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Penny Q. Fang, MD, MBA
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ethan B. Wang, BA
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Sairah Ahmed, MD
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Madeleine Duvic, MD
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Preetesh Jain, MD
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Luis E. Malpica Castillo, MD
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ranjit Nair, MD
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Raphael E. Steiner, MD
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Paolo Strati, MD
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Auris O. Huen, MD, PharmD
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Swaminathan P. Iyer, MD
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Chelsea C. Pinnix, MD, PhD
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Bouthaina S. Dabaja, MD
)
)
)
[14] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jillian R. Gunther, MD, PhD
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2023
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 24521094
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsbas
)
[2] => Array
(
[Type] => issn-locals
[Value] => edsbas.oa
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Advances in Radiation Oncology, Vol 8, Iss 6, Pp 101279- (2023
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |